ZENTECH SA
" Development of specific IVD products to detect the patient serology due to the infection with SARS-COV2 Developement based on ISO13485, Directives 98/79/EC standards. Different technologies approched : ELISA, RT-PCR, lateral flow "
Contact: Alain Bosseloir COO ZenTech sa Liege Science Park Avenue du Pré Aily 10 4031 Angleur
D-tek s.a
" "Multiplex Immuno-Dot technology for COVID-19 serological investigation The Multiplex serological technology, developed since 1995 in D-tek (www.d-tek.be), is dedicated to the profiling of the human antibody response to different immunogens, in a single test. It has various applications in laboratory diagnostics, as well as medical and pharmaceutical research (companion-diagnostics). The technology finds an obvious application for the COVID-19 serological investigation, as the antibody response to the SARS-CoV-2 infection is known to be complex, with multi-epitope targeting, and needs to be better understood. In a typical test (ongoing development), various recombinant SARS-CoV-2 antigens are coated on a membrane strip at different spot positions. The assay is designed to map, in one single test, any patient antibody recognizing any of these protein structures. The test procedure is a classical enzyme immunoassay that can be processed from 10µl of patient's serum or...
Xpress Biologics
" Xpress Biologics, a Belgian based CDMO, has several strategies to tackle the COVID-19 pandemic which includes: - The development of a serology assay to detect Covid-19 seroconversion in humans based on the manufacturing of 3 specific COVID-19 antigens ( full-length Spike protein, S1 subunit, RBD domain) using Pichia pastoris as expression system - Plasmid DNA manufacturing expertise for the development of anti-COVID DNA vaccines - Recombinant protein or antibody fragments manufacturing expertise for diagnostic and treatment of COVID-19 Xpress Biologics has adapted technological platforms that are available to meet the COVID-19 pandemic challenge. In particular our Molecular Biology solution can rapidly help us develop microbial strains for robust and efficient expression of several type of biologics such as viral antigens, neutralizing antibody fragments and DNA vaccines while through our Upstream Process platform we can rapidly engineer industrial processes for...
UMONS/ Haute école Condorcet/ UCLouvain/ Epicura/ Machine sight
" In view of the risk of a respirator shortage in intensive care units throughout the world following the COVID 19 epidemic, a simple solution based on existing means or means that are easy to implement is being sought by a consortium of respiratory physiotherapists, researchers of UMONS, physicians of the the intensive care unit of the Epicura hospital and a mechatronics engineering company. In view of the risk of a respirator shortage in intensive care units throughout the world following the COVID 19 epidemic, a simple solution based on existing means or means that are easy to implement is being sought by a consortium of respiratory physiotherapists, researchers of UMONS, physicians of the the intensive care unit of the Epicura hospital and a mechatronics engineering company. "
Funding: internal funding
Contact: Pr. Alexandre Legrand, head of the laboratory of Physiology and Respiratory Rehabilitation...
Comunicare Solutions
" Comunicare Solutions is a health technology startup, specializing in patient empowerment, self-management and digital therapy. In the context of Covid-19 sanitary crisis, we proposed our solution for the remote support to chronic patients, especially the most at risk patients who suffered from chronic systemic diseases of respiratory origin, such as chronic obstructive pulmonary disease (COPD) and heart disease like heart failure or complex hypertension. The application enables caregivers to inform those patients about additional precautions, to screen patients reported outcomes but also to keep in touch with them via video consultation"
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
Alphadia s.a.
" PCR test to segment Covid-19 patients " and " qRT-PCR to segment Covid patients Cytokines storm "
Funding: No funding requested
Contact: Bernard Noirhomme BDM & Administrator This email address is being protected from spambots. You need JavaScript enabled to view it. +32 471 55 62 24
DNAlytics
" Research projects : contributions to research projects with academics and hospital representatives (-omics data investigations, biomarkers and multi-marker indicators, stratification of populations, predictive models for diagnosis/prognosis, ... Development / production capabilities: internal processes and quality system compatible with ISO.13485 (medical devices). Skills and expertise: data sciences, machine learning and other technologies from artificial intelligence; statistics, bio-IT; model encapsulation into software, mobile apps or web platforms "
Funding: Prestations sub-contracted by lead researchers, or partnerships through regional/EU projects with public funding.
Publication References: Complete list on www.dnalytics.com/publications/
Contact : This email address is being protected from spambots. You need JavaScript enabled to view it.
AEPODIA
" Experts in the early development of drugs and medical devices up to clinical proof-of-concept (from preclinical to Phase 2). Via its network of partners, Aepodia facilitates access to patients and to validated clinical centres throughout Europe. With offices in Belgium and France, Aepodia is a recognized partner for pharmaceutical and biotechnology companies since 2007. "
Contact: www.aepodia.com This email address is being protected from spambots. You need JavaScript enabled to view it.
Diagenode SA
" CE marked of Covid assay by RT-QPCR "
Contact: didier. This email address is being protected from spambots. You need JavaScript enabled to view it.
UCB
" (1) UCB has an active contribution to increase local COVID-19 diagnostic testing capabilities (up to 5000 tests/day) (2) UCB has developed a UCB Global fund to understand and address long term effect of COVID19 on vulnerable populations' health "
Equaly sa
" Novel methods to prevent and treat Covid-19 viral infection by inhibiting virus entry "
Funding: not disclosed
Aesculape CRO Belgium BV
" Treatment of COVID 19 complications with antibodies "
Funding: partly public partly private
Contact : This email address is being protected from spambots. You need JavaScript enabled to view it. 0492 735931
3D-Side S.A.
" "- 3D printing of swabs in SLS - 3D printing of valves - 3D printing of connectors for respiratory systems - Advice on guidelines on the manufacturing and post processing of such devices." "
Contact: Khanh TRAN DUY This email address is being protected from spambots. You need JavaScript enabled to view it.
BECARV SA
" BECARV supplies and install solution and equipement for labs, such as modular biosafety cabinets, air purifier for containment of a room, filter units, etc "
Contact: www.becarv.be Michaël Jeanty This email address is being protected from spambots. You need JavaScript enabled to view it.
Coris BioConcept
" Early February we started the development of a rapid antigen detection assay for SARS-CoV-2. The COVID-19 Ag Respi-Strip Assay was validated in three University hospital laboratories and registered (CE mark) by end of March. The test is designed as a first line triage assay to be used for rapid (15 minutes) detection of SARS-CoV-2 on symptomatic patients. We are currently developing a serological assay that targets the immune response against several antigens of the virus. "
Publication References: https://jcm.asm.org/content/jcm/early/2020/05/11/JCM.00977-20.full.pdf https://www.frontiersin.org/articles/10.3389/fmed.2020.00225/full?utm_campaign=ba-cov-sci-fmed-respi-strip&utm_medium=cvlp&utm_source=fweb
Contact: https://www.corisbio.com/Products/Human-Field/Covid-19.php product-sales: This email address is being protected from spambots. You need JavaScript enabled to view it. science-R&D: This email address is being protected from spambots. You need JavaScript enabled to view it.
